Articles On Kazia Therapeutics (ASX:KZA)
Title | Source | Codes | Date |
---|---|---|---|
Kazia Therapeutics a top-10 finalist in ANZLF Trans-Tasman Innovation and Growth Awards
The four award winners will be announced at a dinner in Auckland, New Zealand, next Thursday, September 12, presented by NZ Prime Minister Jacinta Arden. |
Proactive Investors | KZA | 5 years ago |
Kazia Therapeutics continues to progress clinical assets into FY2020
If GDC-0084 is successful in phase-III, the drug will launch into a disease area that has been poorly served by the last two decades of progress in cancer treatment. |
Proactive Investors | KZA | 5 years ago |
Kazia Therapeutics designated name for brain cancer drug by World Health Organisation
Selection of an INN is usually a necessary step before a new drug can be submitted for commercial registration. |
Proactive Investors | KZA | 5 years ago |
Kazia Therapeutics reaches milestone for Phase 1 Cantrixil trial in ovarian cancer
|
Proactive Investors | KZA | 5 years ago |
Highlights on Health-Related Space from 5 ASX Companies – MXC, NHL, KZA, IHL and AFA
Australia has a well-regulated and high-quality health sector, while its medical research and healthcare infrastructure is of world class. Over the years, the health and medical industry in the country has grown at a rapid pace in terms of... |
Kalkine Media | KZA | 5 years ago |
Kazia Therapeutics concludes recruitment into Part B of its phase I ovarian cancer clinical study
About 240,000 women are diagnosed with ovarian cancer each year worldwide and it is the eighth most common cause of cancer death in women. |
Proactive Investors | KZA | 5 years ago |
Kazia completes recruitment of phase 1 Cantrixil trial
Australian oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) says it has completed recruitment of patients into Part B of its phase 1 clinical study of Cantrixil in ovarian cancer. |
BiotechDispatch | KZA | 5 years ago |
Recent Updates On 4 Healthcare Stocks- BNO, MDR, KZA, OPT
Companies and institutions that provide medical assistance and services, manufactures of medical equipment, engage in clinical trials and development of drugs, are part of the healthcare sector. The Australian government makes significant c... |
Kalkine Media | KZA | 5 years ago |
Kazia Therapeutics to begin phase I clinical trial for cancer that has spread to the brain
Memorial Sloan Kettering Cancer Center in New York will investigate the potential use of Kazia’s investigational new drug, GDC-0084. |
Proactive Investors | KZA | 5 years ago |
Kazia Therapeutics unveils fresh clinical trial for its brain cancer drug candidate
Biotechnology company Kazia Therapeutics (ASX: KZA) has taken a definitive step towards proving the safety and efficacy of its investigational new drug GDC-0084, after announcing a “state of the art” phase 1 clinical trial to be conducted a... |
SmallCaps | KZA | 5 years ago |
Kazia Therapeutics substantial holder Willoughby Capital increases interest to 17.52%
Edison Investment Research has assigned an indicative valuation range of $84–135 million or $1.35–2.17 per share for Kazia. |
Proactive Investors | KZA | 5 years ago |
Kazia Therapeutics substantial shareholder lifts interest to 17.4%
Sydney-based Hishenk Pty Ltd now holds 10.835 million shares after placement and on-market purchases. |
Proactive Investors | KZA | 5 years ago |
Kazia Therapeutics has two novel classes of anti-cancer drugs: Edison Investment Research
A new collaboration with the Alliance for clinical trials in oncology means Kazia will soon have four clinical trials of GDC-0084 underway in primary or secondary brain cancers. |
Proactive Investors | KZA | 5 years ago |
2 Healthcare Stars Under Spotlight – MSB And KZA
The healthcare industry of Australia plays a major role in developing the country’s economy. The healthcare sector witnessed an increase in the demand for health services by Australia’s growing and ageing population. The growth in the indus... |
Kalkine Media | KZA | 5 years ago |